Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0700+0.0300 (+1.47%)
At close: 04:00PM EDT
2.0600 -0.01 (-0.48%)
After hours: 05:29PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close2.0400
Open2.1000
Bid2.0700 x 900
Ask2.2600 x 1400
Day's Range2.0600 - 2.1000
52 Week Range1.8500 - 5.0000
Volume26,298
Avg. Volume104,429
Market Cap189.196M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for IMMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immutep Limited
    Daily – Vickers Top Insider Picks for 07/19/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

    Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 / anti-PD-L1 (“PD-X”) based 1st line therapy1Key facts reported: Median Overall Survival (OS) from therapy with efti in combination with pembrolizumab is 9.7 months25% were progression free at 6 months and 36.5% were alive at 18 months2 Chemo-free therapy of efti in combination with pembrolizumab contin

  • GlobeNewswire

    Immutep Quarterly Activities Report

    Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activityBiomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longerFour world leading oncologists join the Clinical Advisory BoardWell-funded with ~$80 million in cash, giving Immutep an expected cash runway into early

  • GlobeNewswire

    Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

    SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled “Anti-LAG-3 Antibodies” by the Japanese Patent Office. This new Japanese patent follows the grant of the equivalent European patent announced in October 2020. The claims of the patent are directed to

Advertisement
Advertisement